Jazz Pharmaceuticals, Inc. (NASDAQ: JAZZ)
Jazz Pharmaceuticals - integrating innovative products with valuable programs and resources to benefit patients in neurology and psychiatry.
We are a specialty pharmaceutical company that identifies, develops and commercializes innovative products to satisfy unmet medical needs in neurology and psychiatry.
Our unwavering commitment to improving patient care is demonstrated every day through unique patient and physician programs and our ongoing collaboration with patients, physicians and advocacy groups. Building collaborative relationships that foster innovation is the key to our success.
Our Strategy
Our strategy is to build a broad therapeutic portfolio through a combination of internal development and acquisition/in-licensing activities and to utilize our specialty sales force to promote our products in neurology and psychiatry. We apply novel formulation and delivery technologies to well-proven drug molecules and new chemical entities with known mechanisms of action to enhance patient care by improving efficacy, reducing adverse side effects or increasing patient compliance relative to existing therapies.
Our mission is to improve patients’ lives by identifying, developing and commercializing valuable pharmaceutical products in focused therapeutic areas. We address serious conditions in neurology and psychiatry that are poorly understood and undertreated – all with the goal of improving patient care. Keeping patients firmly in mind inspires us to bring innovative and valuable resources to those in need.
Our Focus
Jazz Pharmaceuticals has an unwavering commitment to improving care for patients with serious neurological and psychiatric conditions through innovative treatments. We have an established portfolio of pharmaceutical products and a pipeline of product candidates advancing through various development stages. We continue to work closely with healthcare professionals to identify significant treatment gaps in the areas of neurology and psychiatry.
Our Inspiration
- Addressing poorly understood conditions and underserved patients
- Improving patient care and developing valuable programs for physicians and patients
As an industry innovator, Jazz Pharmaceuticals takes a focused approach to treating serious conditions that are poorly understood and patient populations who are underserved, as demonstrated by our products and pipeline. We have an unwavering commitment to improving patient care and developing distinctive and valuable programs for patients and physicians. Patients affected by the conditions we focus on (such as narcolepsy, social anxiety disorder and fibromyalgia) are often misdiagnosed, and many may never be properly diagnosed or treated. We believe these patient populations should not be ignored. We are committed to helping patients with neurological and psychiatric disorders better understand their condition and receive accurate diagnosis and effective treatment. We partner with physicians and support patient advocacy groups to further public education and develop unique tools and resources for patients.
Our Approach to R&D
- Mitigate risks and reduce the cost and time to develop products
- Commercialize therapies which address significant unmet needs to improve patients’ lives
Our novel development approach has been designed to reduce the cost and time associated with the development and commercialization of new therapies which address patient needs and result in significant market opportunities. The focus of our development activities is to bring to market products that improve patients’ lives. Once products are approved, our goal is to promote them through our specialty sales force. Our portfolio is built through internally-identified product concepts and focused acquisition and in-licensing activities.
Significant unmet therapeutic needs similarly exist for a wide range of neurological and psychiatric disorders. An estimated 26 percent of Americans 18 years and older suffer from a diagnosable mental disorder in a given year, which translates into nearly 58 million people and makes it more than the disease burden caused by all types of cancers. Up to 70 million Americans suffer from debilitating sleep conditions, the majority of which are neither diagnosed nor appropriately treated, according to the National Heart, Lung and Blood Institute.
Our Pipeline
Product Development Process
Our process for identifying and developing product candidates draws on market research, new product planning activities, interactions with thought leaders in neurology and psychiatry, and research and development. Jazz Pharmaceuticals selects not only the most promising compounds, but also the drug delivery technology that will optimize that promise. Once a potential product candidate is identified, we conduct feasibility activities to help us determine whether a product candidate has the requisite pharmacological activity, would be valuable to patients and healthcare providers, and could be developed within an acceptable timeframe and budget.
Our JZP-7 and JZP-8 product candidates resulted from our in-house program to identify product candidates. Several other product candidates identified through this process are in various stages of development.
Lowering Risk, Speeding Development –
- Obtain proof-of-concept before incurring significant development expenses
- Identify activities and milestones at each development stage to reduce risk
- Shorten development cycle by working with well-proven drug molecules and new substances with known mechanisms of action
We focus our early-stage activities on obtaining proof-of-concept for each product candidate at a relatively low cost to identify and lessen risk before we incur significant development expenses.
Activities and milestones at each stage of development are designed to further reduce risk, so that as a product candidate moves through the stages of development we can confidently allocate additional resources. If a product candidate does not successfully meet our requirements at any stage of development, we terminate the project.
Our program is also designed to shorten the development cycle for our product candidates compared with that for most new chemical entities. Because we generally work with known drug compounds, or compounds with a mechanism of action or chemical structure that is the same as or similar to that of marketed products, we can often move from a proof-of-concept study directly into pivotal clinical trials.
If we are able to complete product development with fewer clinical trials than are required for a new chemical entity, we may have lower costs of development and shorter development timelines.
We review our portfolio periodically to ensure that we have a balanced mix of product candidates moving into development.
Science & Technology –
Our R&D staff is an interactive team of formulation, preclinical and pharmacokinetic experts. Once an unmet medical need is identified, the team determines the best compound and the optimal drug delivery and pharmacokinetic profile. Our goal is to maximize efficacy and patient compliance while minimizing side effects. The best delivery technology and route of administration to meet this target product profile is selected and optimized for patient use and commercial development. Jazz Pharmaceuticals is not constrained or committed to any specific delivery technology, but seeks collaborations that will result in the most beneficial outcomes for patients. Jazz Pharmaceuticals scientists apply creative and innovative solutions when developing novel approaches to delivery technologies and product development including but not limited to transdermal, intranasal, immediate and controlled release oral formulations.
Patient Advocacy
We provide continuing support to healthcare advocacy groups and scientific organizations. We collaborated with the Narcolepsy Network to produce a national public service campaign, educational brochures and DVDs distributed through physician offices to help raise awareness of this troubling sleep-wake disorder. We also support the efforts of the Anxiety Disorders Association of America to promote public and professional awareness of the enormous impact that anxiety disorders have on the lives of patients and their family and friends.
Patient Assistance
Jazz Pharmaceuticals currently provides Patient Assistance for U.S. patients.
Xyrem® (sodium oxybate) oral solution:
Reimbursement assistance is available for U.S. patients who are uninsured or underinsured, through the XYREM Success Program®. For more information and an application, please call 1-866-XYREM88 (1-866-997-3688).
Luvox CR® (fluvoxamine maleate) Extended-Release Capsules:
Co-pay assistance is available through a point-of-sale rebate card which provides patients up to $25 off of their out-of-pocket prescription or co-payment costs at the pharmacy.
Click for restrictions of use.
Rebates are not valid for prescriptions reimbursed under any federal or state healthcare program, including any state medical assistance programs. Offer not valid in Massachusetts and void where prohibited by law, taxed, or restricted.
Please visit the www.LuvoxCR.com website for more information.
Patient Resources
We are committed to supporting and providing resources for the patients who inspire us. Because cognitive behavioral therapy (CBT) can be an important part of a comprehensive treatment plan for patients with obsessive compulsive disorder (OCD), Jazz Pharmaceuticals supported the development of CT STEPS™.
CT STEPS is a program designed for OCD patients by Dr. John Greist and his colleagues, Dr. Lee Baer and Dr. Isaac Marks. It was originally created as a phone-based program for OCD, but through the use of the internet, it has now been made into an interactive tool that is accessible 24 hours a day to help patients monitor their own progress confidentially.
CT STEPS is not designed to replace behavioral therapists. Instead, it is designed to provide a service for use in addition to behavioral therapy or for patients who may not have access to behavioral therapy. CT STEPS has not been studied in combination with pharmacotherapy
Learn About Nicole’s Story
“I’m so glad that I got diagnosed and treated for my symptoms of narcolepsy. It’s really made a difference in my life.” – Nicole Jeray, LPGA golfer & narcolepsy patient
Like the musical form that inspired our name…
Our company’s name, Jazz Pharmaceuticals, captures our philosophy of excellence in innovation and collaboration as we work together to improve patients’ lives. We are building an environment that values and encourages individual excellence, intensive and productive collaboration and innovation.
|
